

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 230 375 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**06.07.2005 Bulletin 2005/27**

(51) Int Cl.7: **C12N 15/63**, C12N 15/11,  
A61K 31/713, A01K 67/027,  
C12N 5/10

(21) Application number: **00976188.3**

(86) International application number:  
**PCT/GB2000/004404**

(22) Date of filing: **17.11.2000**

(87) International publication number:  
**WO 2001/036646 (25.05.2001 Gazette 2001/21)**

### (54) INHIBITING GENE EXPRESSION WITH DSRNA

HEMMUNG DER EXPRESSION VON GENEN MITTELS DSRNA

INHIBITION D'EXPRESSION GENIQUE A L'AIDE D'ARN BICATENAIRE

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**LT LV**

(56) References cited:  
**EP-A- 1 197 567 WO-A-00/01846**  
**WO-A-00/44914 WO-A-00/63364**  
**WO-A-97/07668 WO-A-98/05770**  
**WO-A-99/32619**

(30) Priority: **19.11.1999 GB 9927444**

(43) Date of publication of application:  
**14.08.2002 Bulletin 2002/33**

(60) Divisional application:  
**04022291.1**

(73) Proprietor: **Cancer Research Technology Limited**  
**London WC2A 3PX (GB)**

(72) Inventors:  
• **Zernicka-Goetz, Magdalena** Cambridge House  
London NW1 4JL (GB)  
• **Wianny, Florence** Cambridge House  
London NW1 4JL (GB)  
• **Evans, Martin John** Cambridge House  
London NW1 4JL (GB)  
• **Glover, David Moore** University of Cambridge,  
Cambridge, CB2 3DY (GB)

(74) Representative: **Lee, Nicholas John et al**  
**Kilburn & Strode,**  
**20 Red Lion Street**  
**London WC1R 4PJ (GB)**

- **FIRE A: "RNA-triggered gene silencing"**  
**TRENDS IN GENETICS**, vol. 15, no. 9, 1  
**September 1999 (1999-09-01)**, pages 358-363,  
XP004176656 ISSN: 0168-9525 cited in the  
application
- **BEVILACQUA A ET AL: "ANTISENSE RNA**  
**INHIBITS ENDOGENOUS GENE EXPRESSION IN**  
**MOUSE PREIMPLANTATION EMBRYOS LACK**  
**OF DOUBLE-STRANDED RNA MELTING**  
**ACTIVITY" PROCEEDINGS OF THE NATIONAL**  
**ACADEMY OF SCIENCES OF THE UNITED**  
**STATES**, vol. 85, no. 3, 1988, pages 831-835,  
XP002164293 ISSN: 0027-8424 cited in the  
application
- **ZERNICKA-GOETZ MET AL: "Following cell fate**  
**in the living mouse embryo" DEVELOPMENT**,  
vol. 124, no. 6, 1 March 1997 (1997-03-01), pages  
1133-1137, XP002086618 ISSN: 0950-1991 cited  
in the application
- **WIANNY F ET AL: "Specific interference with**  
**gene function by double-stranded RNA in early**  
**mouse development" NATURE CELL BIOLOGY**,  
vol. 2, no. 2, February 2000 (2000-02), pages  
70-75, XP002138445 ISSN: 1465-7392

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 230 375 B1**

## Description

[0001] The present invention relates to inhibiting gene expression. In particular, it relates to inhibiting gene expression in mammals using double stranded RNA (dsRNA).

[0002] The benefits of being able to inhibit the expression of a specific gene or group of genes in mammals are obvious. Many diseases (such as cancer, endocrine disorders, immune disorders and so on) arise from the abnormal expression of a particular gene or group of genes within a mammal - the inhibition of the gene or group can therefore be used to treat these conditions. Similarly, disease can result through expression of a mutant form of protein, in which case it would be advantageous to eliminate the expression of the mutant allele. In addition, such gene specific inhibition may be used to treat viral diseases which are caused by for example retroviruses, such as HIV, in which viral genes are integrated into the genome of their host and expressed.

[0003] In addition, the elimination or inhibition of expression of a specific gene can be used to study and manipulate early developmental events in the non-human embryo. The most valuable information would be obtained if the function of the gene of interest could be disturbed in specific cells of the embryo and at defined times. In such a situation, in the mouse model, the classical techniques of gene "knockout" cannot be used, because they eliminate gene function universally throughout the embryo. Furthermore, if a gene is repeatedly used in space and time to direct developmental processes, elimination of its role by conventional gene "knockout" may deny an understanding of everything but the first event. Even when the interest is to study the very first time in development at which a gene functions, the contribution of maternal transcripts and their translation products can mask the effects of the gene knockout. Existing "knockout" technology is also extremely laborious. It necessitates first making a disrupted gene segment that is suitably marked to enable the selection of homologous recombination events in cultured embryonic stem cells. Such cells must then be incorporated into blastocysts and the resulting chimaeric animals used to establish pure breeding lines before homozygous mutants can be obtained.

[0004] It is known that expression of genes can be specifically inhibited by double stranded RNA in certain organisms. Double stranded RNA interference (RNAi) of gene expression was first shown in *Caenorhabditis elegans* (Fire *et al. Nature* **391**, 806-811 (1998); WO99/32619), has recently been shown to be effective in lower eukaryotes including *Drosophila melanogaster* (Kennerdell & Carthew, *Cell* **95**, 1017-1026 (1998)), *Trypanosoma brucei* (Ngo, *et al. Proc Natl Acad Sci USA* **95**, 14687-14692 (1998)), planarians (Sanchez Alvarado & Newmark, *Proc Natl Acad Sci U S A* **96**, 5049-5054 (1999)) and plants (Waterhouse, *et al. Proc Natl Acad Sci U S A* **95**, 13959-13964 (1998)). The application of this approach has also been demonstrated in Zebrafish embryos, but with limited success (Wargelius, *et al. Biochem Biophys Res Commun* **263**, 156-161 (1999)).

[0005] To date, there has been no report that RNAi can be used in mammals and moreover there is a belief in the art that RNAi will not function in mammals. In this respect, concern has been expressed that the protocols used for invertebrate and plant systems are unlikely to be effective in mammals (reviewed by Fire (Fire *Trends Genet* **15**, 358-363 (1999)). This is because accumulation of dsRNA in mammalian cells can result in a general block to protein synthesis. The accumulation of very small amounts of double stranded RNA (dsRNA) in mammalian cells following viral infection results in the interferon response (Marcus, *Interferon* **5**, 115-180 (1983)) which leads to an overall block to translation and the onset of apoptosis (Lee & Esteban *Virology* **199**, 491-496 (1994)). Part of the interferon response is the activation of a dsRNA responsive protein kinase (PKR) (Clemens, *Int J Biochem Cell Biol* **29**, 945-949 (1997)). This enzyme phosphorylates and inactivates translation factor EIF2 $\alpha$  in response to dsRNA. The consequence is a global suppression of translation, which in turn triggers apoptosis. Wagner & Sun. (*Nature* **391**, 806-811 (1998)) suggest that RNAi will not work in mammals because it has no effect when used as a control in experiments into anti-sense RNA.

[0006] Anti-sense RNA has been attempted as a means of reducing gene expression in the embryos of a number of species. Whereas it has had considerable success in *Drosophila*, it has been disappointing in Zebrafish, *Xenopus* and mouse embryos. In *Xenopus*, there were some limitations in using the antisense approach. This is thought to be due to a prominent RNA melting activity (Bass, & Weintraub, *Cell* **48**, 607-613 (1987); Rebaghati & Melton, *Cell* **48**, 599-605 (1987)), exerted by the dsRNA specific adenosine deaminase (dsRAD), and suggests that RNAi is not likely to be successful.

[0007] In the mouse embryo, anti-sense RNA has had inconsistent and limited success in reducing gene expression, particularly between the two-four cell stages (Bevilacqua, *et al. Proc Natl Acad Sci USA* **85**, 831-835 (1988)). These authors were concerned that the partial inhibition of  $\beta$ -glucuronidase in their experiments might also reflect a melting activity acting upon sense/anti-sense duplexes, and so they examined the stability of  $\beta$ -glucuronidase dsRNA micro-injected into mouse blastomeres. They reported no effects on RNA stability, but this was only followed over a period of 5 hours. Thus, there is no suggestion in this paper that dsRNA can persist in mammalian cells long enough to interfere with gene expression. In addition, they reported no effects upon the expression of  $\beta$ -glucuronidase following the injection of dsRNA. Thus, this paper does not suggest that dsRNA can inhibit gene expression in mammalian cells.

[0008] WO99/32619 suggests that dsRNA can be used to inhibit gene expression in mammals. However, the only experimental evidence in this document shows that RNAi works in *C. elegans*; there is nothing to show that it could

work in mammals. Indeed, later publications by the inventors listed for WO99/32619 (Fire, *Trends Genet* **15**, 358-363 (1999), (Montgomery & Fire, *Trends Genet* **14**, 255-258 (1998)) state that RNAi could only be made to work in mammals if the PKR response could be neutralised or some way avoided, although no suggestions are provided in WO99/32619 for how this might be achieved. These later publications indicate that the inventors of WO99/32619 themselves believe that RNAi has not yet been (and cannot be) made to work in mammals.

**[0009]** Thus, there is a perception in the art that RNAi cannot be made to work in mammals. Contrary to this perception, the inventors have now shown that it is possible to interfere with specific gene expression in the mouse oocyte and zygote following microinjection of the appropriate dsRNA. They have shown experimentally that RNAi can phenocopy the effects of disrupting the maternal expression of the *c-mos* gene in the oocyte to overcome the arrest of meiosis at metaphase II, or the zygotic expression of E-cadherin to prevent development of the blastocyst as observed in the corresponding knockout mice. The inventors have shown that the injection of a dsRNA is specific to the corresponding gene; it does not cause a general translational arrest, because embryos continue to develop and no signs of cell death can be observed. Thus, they have shown that RNAi can be effective in mammalian cells.

**[0010]** According to a first aspect of the present invention, there is provided a RNA comprising a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene in a mammalian cell or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template, or an expression vector encoding such an RNA, for use as a medicament.

**[0011]** According to a second aspect of the invention, there is provided an *in vitro* method for inhibiting the expression of a target gene in a mammalian cell, the method comprising:

introducing into the cell an RNA comprising a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of the target gene or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template; and verifying inhibition of expression of the target gene,

wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

**[0012]** dsRNA useful in accordance with the invention is derived from an "endogenous template". Such a template may be all or part of a nucleotide sequence endogenous to the mammal; it may be a DNA gene sequence or a cDNA produced from an mRNA isolated from the mammal, for example by reverse transcriptase. When the template is all or a part of a DNA gene sequence, it is preferred if it is from one or more or all exons of the gene. Additionally, all or part of a viral gene may form an endogenous template, if it is expressed in the mammal in such a way that the interferon response is not induced, e.g. expression from a pro-virus integrated into the host cell chromosome. Thus, the dsRNA of the present invention is distinguished from viral dsRNA and synthetic polyrIC, both of which have been observed to induce PKR which leads to apoptosis in mammalian cells.

**[0013]** Whilst the dsRNA is derived from an endogenous template, there is no limitation on the manner in which it is synthesised. Thus, it may be synthesised *in vitro* or *in vivo*, using manual and/or automated procedures. *In vitro* synthesis may be chemical or enzymatic, for example using cloned RNA polymerase (e.g., T3, T7, SP6) for transcription of the endogenous DNA (or cDNA) template, or a mixture of both.

**[0014]** *In vivo*, the dsRNA may be synthesised using recombinant techniques well known in the art (see e.g., Sambrook, et al., MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D. N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M. J. Gait ed. 1984); NUCLEIC ACID HYBRIDISATION (B. D. Hames & S. J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B. D. Hames & S. J. Higgins eds. 1984), ANIMAL CELL CULTURE (R. I. Freshney ed. 1986); IMMOBILISED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J. H. Miller and M. P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, VOLUMES I-IV (D. M. Weir and C C. Blackwell eds 1986).

**[0015]** Thus, bacterial cells can be transformed with an expression vector which comprises the DNA template from which the dsRNA is to be derived. Alternatively, the cells of the mammal in which inhibition of gene expression is required may be transformed with an expression vector or by other means. Bidirectional transcription of one or more copies of the template may be by endogenous RNA polymerase of the transformed cell or by a cloned RNA polymerase (e.g., T3, T7, SP6) coded for by the expression vector or a different expression vector. The use and production of an expression construct are known in the art (see WO98/32016; US Pat Nos. 5,593,874, 5,698,425, 5,712,135, 5,789,214,

and 5,804,693). Inhibition of gene expression may be targeted by specific transcription in an organ, tissue, or cell type; an environmental condition (e.g. infection, stress, temperature, chemical); and/or engineering transcription at a developmental stage or age, especially when the dsRNA is synthesised *in vivo* in the mammal. dsRNA may also be delivered to specific tissues or cell types using known gene delivery systems. Known eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. These vectors are listed solely by way of illustration of the many commercially available and well known vectors that are available to those of skill in the art.

**[0016]** If synthesised outside the mammalian cell, the RNA may be purified prior to introduction into the cell. Purification may be by extraction with a solvent (such as phenol/chloroform) or resin, precipitation (for example in ethanol), electrophoresis, chromatography, or a combination thereof. However, purification may result in loss of dsRNA and may therefore be minimal or not carried out at all. The RNA may be dried for storage or dissolved in an aqueous solution, which may contain buffers or salts to promote annealing, and/or stabilisation of the RNA strands.

**[0017]** dsRNA useful in the present invention includes dsRNA which contains one or more modified bases, and dsRNA with a backbone modified for stability or for other reasons. For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulphur heteroatom. Moreover, dsRNA comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, can be used in the invention. It will be appreciated that a great variety of modifications have been made to RNA that serve many useful purposes known to those of skill in the art. The term dsRNA as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of dsRNA, provided that it is derived from an endogenous template.

**[0018]** The double-stranded structure may be formed by a single self-complementary RNA strand or two separate complementary RNA strands. RNA duplex formation may be initiated either inside or outside the mammalian cell.

**[0019]** The dsRNA comprises a double stranded structure, the sequence of which is at least 80% identical to at least a part of the target gene. "Identity", as known in the art, is the relationship between two or more polynucleotide (or polypeptide) sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polynucleotide sequences, as determined by the match between strings of such sequences. Identity can be readily calculated (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Grib-skov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide sequences, the term is well known to skilled artisans (*Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; *Sequence Analysis Primer*, Grib-skov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, **48**: 1073 (1988).

**[0020]** Methods commonly employed to determine identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, **48**:1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., *Nucleic Acids Research* **12**(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* **215**: 403 (1990)). Another software package well known in the art for carrying out this procedure is the CLUSTAL program. It compares the sequences of two polynucleotides and finds the optimal alignment by inserting spaces in either sequence as appropriate. The identity for an optimal alignment can also be calculated using a software package such as BLASTx. This program aligns the largest stretch of similar sequence and assigns a value to the fit. For any one pattern comparison several regions of similarity may be found, each having a different score. One skilled in the art will appreciate that two polynucleotides of different lengths may be compared over the entire length of the longer fragment. Alternatively small regions may be compared. Normally sequences of the same length are compared for a useful comparison to be made.

**[0021]** It is preferred is there is 100% sequence identity between the inhibitory RNA and the part of the target gene. However, dsRNA having 80% or greater than 90% or 95% sequence identity may be used in the present invention, and thus sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence can be tolerated.

**[0022]** The duplex region of the RNA may have a nucleotide sequence that is capable of hybridising with a portion of the target gene transcript (e.g., 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours; followed by washing).

**[0023]** Whilst the optimum length of the dsRNA may vary according to the target gene and experimental conditions, the duplex region of the RNA may be at least 25, 50, 100, 200, 300, 400 or more bases long.

**[0024]** As used herein "target gene" generally means a polynucleotide comprising a region that encodes a polypeptide, or a polynucleotide region that regulates replication, transcription or translation or other processes important to expression of the polypeptide, or a polynucleotide comprising both a region that encodes a polypeptide and a region

operably linked thereto that regulates expression. Target genes may be cellular genes present in the genome or viral and pro-viral genes that do not elicit the interferon response, such as retroviral genes. The target gene may be a protein-coding gene or a non-protein coding gene, such as a gene which codes for ribosomal RNAs, splicosomal RNA, tRNAs, etc.

**[0025]** It is preferred if the dsRNA is substantially identical to the whole of the target gene, i.e. the coding portion of the gene. However, the dsRNA can be at least 80% identical to a part of the target gene. The size of this part depends on the particular target gene and can be determined by those skilled in the art by varying the size of the dsRNA and observing whether expression of the gene has been inhibited.

**[0026]** In the present invention, dsRNA can be used to inhibit a target gene which causes or is likely to cause disease, i.e. it can be used for the treatment or prevention of disease. In the prevention of disease, the target gene may be one which is required for initiation or maintenance of the disease, or which has been identified as being associated with a higher risk of contracting the disease.

**[0027]** In the treatment of disease, the dsRNA can be brought into contact with the cells or tissue exhibiting the disease. For example, dsRNA substantially identical to all or part of a mutated gene associated with cancer, or one expressed at high levels in tumour cells, e.g. aurora kinase, may be brought into contact with or introduced into a cancerous cell or tumour gene. Examples of cancers which the present invention can be used to prevent or treat include solid tumours and leukaemias, including: apudoma, choristoma, branchioma, malignant carcinoid syndrome, carcinoid heart disease, carcinoma (e.g., Walker, basal cell, basosquamous, Brown-Pearce, ductal, Ehrlich tumour, *in situ*, Krebs 2, Merkel cell, mucinous, non-small cell lung, oat cell, papillary, scirrhous, bronchiolar, bronchogenic, squamous cell, and transitional cell), histiocytic disorders, leukaemia (e.g., B cell, mixed cell, null cell, T cell, T-cell chronic, HTLV-II-associated, lymphocytic acute, lymphocytic chronic, mast cell, and myeloid), histiocytosis malignant, Hodgkin disease, immunoproliferative small, non-Hodgkin lymphoma, plasmacytoma, reticuloendotheliosis, melanoma, chondroblastoma, chondroma, chondrosarcoma, fibroma, fibrosarcoma, giant cell tumours, histiocytoma, lipoma, liposarcoma, mesothelioma, myxoma, myxosarcoma, osteoma, osteosarcoma, Ewing sarcoma, synovioma, adenofibroma, adenolymphoma, carcinosarcoma, chordoma, cranio-pharyngioma, dysgerminoma, hamartoma, mesenchymoma, mesonephroma, myosarcoma, ameloblastoma, cementoma, odontoma, teratoma, thymoma, trophoblastic tumour, adeno-carcinoma, adenoma, cholangioma, cholesteatoma, cylindroma, cystadenocarcinoma, cystadenoma, granulosa cell tumour, gynandroblastoma, hepatoma, hidradenoma, islet cell tumour, Leydig cell tumour, papilloma, Sertoli cell tumour, theca cell tumour, leiomyoma, leiomyosarcoma, myoblastoma, myoma, myosarcoma, rhabdomyoma, rhabdomyosarcoma, ependymoma, ganglioneuroma, glioma, medulloblastoma, meningioma, neurilemmoma, neuroblastoma, neuroepithelioma, neurofibroma, neuroma, paraganglioma, paraganglioma nonchromaffin, angiokeratoma, angiolymphoid hyperplasia with eosinophilia, angioma sclerosing, angiomatosis, glomangioma, hemangioendothelioma, hemangioma, hemangiopericytoma, hemangiosarcoma, lymphangioma, lymphangiomyoma, lymphangiosarcoma, pinealoma, carcinosarcoma, chondrosarcoma, cystosarcoma, phyllodes, fibrosarcoma, hemangiosarcoma, leiomyosarcoma, leukosarcoma, liposarcoma, lymphangiosarcoma, myosarcoma, myxosarcoma, ovarian carcinoma, rhabdomyosarcoma, sarcoma (e.g., Ewing, experimental, Kaposi, and mast cell), neoplasms (e.g., bone, breast, digestive system, colorectal, liver, pancreatic, pituitary, testicular, orbital, head and neck, central nervous system, acoustic, pelvic respiratory tract, and urogenital), neurofibromatosis, and cervical dysplasia, and other conditions in which cells have become immortalised or transformed. The invention could be used in combination with other treatments, such as chemotherapy, cryotherapy, hyperthermia, radiation therapy, and the like.

**[0028]** The present invention may also be used in the treatment and prophylaxis of other diseases, especially those associated with expression or overexpression of a particular gene or genes. For example, expression of genes associated with the immune response could be inhibited to treat/prevent autoimmune diseases such as rheumatoid arthritis, graft-versus-host disease, etc. In such treatment, the dsRNA may be used in conjunction with immunosuppressive drugs. The most commonly used immunosuppressive drugs currently include corticosteroids and more potent inhibitors like, for instance, methotrexate, sulphasalazine, hydroxychloroquine, 6-MP/azathioprine and cyclosporine. All of these treatments have severe side-effects related to toxicity, however, and the need for drugs that would allow their elimination from, or reduction in use is urgent. Other immunosuppressive drugs include the gentler, but less powerful non-steroid treatments such as Aspirin and Ibuprofen, and a new class of reagents which are based on more specific immune modulator functions. This latter class includes interleukins, cytokines, recombinant adhesion molecules and monoclonal antibodies. The use of dsRNA to inhibit a gene associated with the immune response in an immunosuppressive treatment protocol could increase the efficiency of immunosuppression, and particularly, may enable the administered amounts of other drugs, which have toxic or other adverse effects to be decreased.

**[0029]** The following classes of possible target genes are examples of the genes which the present invention may be used to inhibit: developmental genes (e.g., adhesion molecules cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines/lymphokines and their receptors, growth/differentiation factors and their receptors, neurotransmitters and their receptors); oncogenes (e.g., ABLI, BCL1, BCL2, BCL6, CBFA2, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETS1, ETV6, FGR, FOS, FYN, HCR, HRAS, JUN,

KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3 and YES); tumour suppresser genes (e.g., APC, BRCA1, BRCA2, MADH4, MCC, NF1, NF2, RB1, TP53 and WT1); and enzymes (e.g., ACP desaturases and hydroxylases, ADP-glucose pyrophorylases, ATPases, alcohol dehydrogenases, amylases, amyloglucosidases, catalases, cellulases, cyclooxygenases, decarboxylases, dextrinases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, GTPases, helicases, hemicellulases, integrases, invertases, isomerases, kinases, lactases, lipases, lipoxygenases, lysozymes, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, polygalacturonases, proteinases and peptideases, pullanases, recombinases, reverse transcriptases, topoisomerases, and xylanases).

**[0030]** In a preferred embodiment of the first aspect, the dsRNA is not derived from  $\beta$ -glucuronidase. In a further aspect, the present invention provides an *in vitro* method for inhibiting the expression of a target gene in a mammalian cell, the method comprising:

introducing into the cell an RNA comprising a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of the target gene or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template, wherein the dsRNA is not derived from  $\beta$ -glucuronidase wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

**[0031]** Inhibition of the expression of a target gene can be verified by observing or detecting an absence or observable decrease in the level of protein encoded by a target gene (this may be detected by for example a specific antibody or other techniques known to the skilled person) and/or mRNA product from a target gene (this may be detected by for example hybridisation studies) and/or phenotype associated with expression of the gene. In the context of a medical treatment, verification of inhibition of the expression of a target gene may be by observing a change in the disease condition of a subject, such as a reduction in symptoms, remission, a change in the disease state and so on. Preferably, the inhibition is specific, i.e. the expression of the target gene is inhibited without manifest effects on the other genes of the cell.

**[0032]** The amount of dsRNA administered to a mammal for effective gene inhibition will vary between wide limits according to a variety of factors, including the route of administration, the age, size and condition of the mammal, the gene which is to be inhibited, the disease or disorder to be treated and so on. The present inventors have found that, when injecting 10  $\mu$ l into a non-human oocyte or cell of the non-human early embryo, solutions having dsRNA at a concentration in the range of from 0.01 to 40 mg/ml, preferably 0.1 to 4 mg/ml and most preferable 0.1 to 2 mg/ml are effective. Thus, the dsRNA may be administered to provide 0.1 to 400 pg, preferably 1 to 40 pg and most preferably 1 to 20 pg in each cell.

**[0033]** The cell having the target gene may be somatic, totipotent or pluripotent, dividing or non-dividing, epithelium, immortalised or transformed, from the non-human germ line, or the like. The cell may be a stem cell or a differentiated cell. Cell types that are differentiated include adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine or exocrine glands. The cell may be any individual cell of the non-human early embryo, and may be a non-human blastocyte. Alternatively, it may be a non-human oocyte. It is known that mammalian cells can respond to extracellular dsRNA and therefore may have a transport mechanism for dsRNA (Asher *et al*, *Nature* **223** 715-717 (1969)). Thus dsRNA may be administered extracellularly into a cavity, interstitial space, into the circulation of a mammal, or introduced orally. Methods for oral introduction include direct mixing of the RNA with food of the mammal, as well as engineered approaches in which a species that is used as food is engineered to express the RNA, then fed to the mammal to be affected. For example, food bacteria, such as *Lactococcus lactis*, may be transformed to produce the dsRNA (see WO93/17117, WO97/14806). Vascular or extravascular circulation, the blood or lymph systems and the cerebrospinal fluid are sites where the RNA may be injected.

**[0034]** RNA may be introduced into the cell intracellularly. Physical methods of introducing nucleic acids may also be used in this respect. The dsRNA may be administered using the microinjection techniques described in Zernicka-Goetz, *et al*. *Development* **124**, 1133-1137 (1997) and Wianny, *et al*. *Chromosoma* **107**, 430-439 (1998).

**[0035]** Other physical methods of introducing nucleic acids intracellularly include bombardment by particles covered by the RNA, for example gene gun technology in which the dsRNA is immobilised on gold particles and fired directly at the site of wounding. Thus, the invention provides the use of an RNA comprising a double stranded structure having a nucleotide sequence, which is substantially identical to at least a part of a target gene in a mammalian cell and which is derived from an endogenous template, in a gene gun for inhibiting the expression of the target gene. Further, there is provided a composition suitable for gene gun therapy comprising: an RNA comprising a double stranded structure having a nucleotide sequence which is substantially identical to at least a part of a target gene in a mammalian cell

and which is derived from an endogenous template; and gold particles. An alternative physical method includes electroporation of cell membranes in the presence of the RNA. dsRNA can be introduced into non-human embryonic cells by electroporation using conditions similar to those generally applied to cultured cells. Precise conditions for electroporation depend on the device used to produce the electro-shock and the dimensions of the chamber used to hold the embryos. This method permits RNAi on a large scale. Any known gene therapy technique can be used to administer the RNA. A viral construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of RNA encoded by the expression construct. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, such as calcium phosphate, and the like. Thus, the RNA may be introduced along with components that perform one or more of the following activities: enhance RNA uptake by the cell, promote annealing of the duplex strands, stabilise the annealed strands, or otherwise increase inhibition of the target gene. A non-human transgenic mammal that expresses RNA from a recombinant construct may be produced by introducing the construct into a zygote, an embryonic stem cell, or another multipotent cell derived from the appropriate mammal.

**[0036]** In another aspect, the invention provides the use of an RNA, or expression vector encoding such an RNA, as defined in the first aspect, in the manufacture of a medicament for inhibiting the expression of a target gene in a mammalian cell, wherein the target gene causes or is likely to cause disease and wherein the mammalian cell is a somatic cell or a cell of a non-human pre-implantation embryo.

**[0037]** The medicament will usually be supplied as part of a sterile, pharmaceutical composition which will normally include a pharmaceutically acceptable carrier. Thus, the invention also provides a pharmaceutical formulation comprising an RNA as defined in the first aspect, or an expression vector encoding such an RNA, together with a pharmaceutically acceptable carrier.

**[0038]** This pharmaceutical composition may be in any suitable form, (depending upon the desired method of administering it to a patient). It may be provided in unit dosage form, will generally be provided in a sealed container and may be provided as part of a kit.

**[0039]** Such a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.

**[0040]** The pharmaceutical composition may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by admixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.

**[0041]** Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions). Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof. Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semisolid, or liquid polyols etc.

**[0042]** For the preparation of solutions and syrups, excipients which may be used include for example water, polyols and sugars. For the preparation of suspensions oils (e.g. vegetable oils) may be used to provide oil-in-water or water in oil suspensions.

**[0043]** Pharmaceutical compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For infections of the eye or other external tissues, for example mouth and skin, the compositions are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base. Pharmaceutical compositions adapted for topical administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent. Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.

**[0044]** Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or enemas.

**[0045]** Pharmaceutical compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500  $\mu\text{m}$  which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

**[0046]** Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.

**[0047]** Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

**[0048]** Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile



injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Excipients which may be used for injectable solutions include water, alcohols, polyols, glycerine and vegetable oils, for example. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

[0049] The pharmaceutical compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts (substances of the present invention may themselves be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents or antioxidants. They may also contain therapeutically active agents in addition to the substance of the present invention.

[0050] Dosages of the substance of the present invention can vary between wide limits, depending upon the disease or disorder to be treated, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used. This dosage may be repeated as often as appropriate. If side effects develop the amount and/or frequency of the dosage can be reduced, in accordance with normal clinical practice.

[0051] The present invention may be used alone or as a component of a kit having at least one of the reagents necessary to carry out the *in vitro* or *in vivo* introduction of RNA to subjects. Preferred components are the dsRNA and a vehicle that promotes introduction of the dsRNA. Such a kit may also include instructions to allow a user of the kit to practice the invention.

[0052] According to a further aspect of the present invention, there is provided a kit for inhibiting expression of a target gene in a mammalian cell, the kit comprising:

RNA which comprises a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene in the mammalian cell or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template or an expression vector encoding such an RNA; and  
a vehicle that promotes introduction of the RNA or vector to the mammalian cell,

wherein the RNA is not derived from the gene encoding  $\beta$ -glucuronidase and wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

[0053] The present invention may be used to manipulate gene expression in the non-human oocyte to treat infertility. It may also be used to regulate the processes of chromosome disjunction in non-human mammals. In humans, there is an increased incidence of chromosome non-disjunction in mothers over 35 years of age, leading to Down's syndrome offspring and spontaneous abortion. A number of cell cycle regulatory molecules are now known that promote several aspects of cycle progression that include cyclin dependent kinases, cyclins, polo kinase, aurora kinase, min A kinase, protein phosphatases, compounds of the anaphase promoting complex and its regulatory molecules, compounds of the proteasome, the SCF complex, compounds of the centrosome, components of the kinetochore, structural proteins of chromosomes, DNA replication enzymes, DNA recombination proteins and DNA repair proteins. The invention may be used in non-humans to modulate the expression of one or more of the above proteins to ensure correct segregation of chromosomes.

[0054] The invention may also be used to manipulate the cell cycle stages of recipient enucleated zygotes and donor cells that provide the nuclei for the cloning of non-human mammals (see WO97/07668). Experience with the cloning of sheep and mice shows a need to optimise the cell cycle stage of the recipient egg prior to its enucleation, and to take down nuclei from cells at a specific stage, frequently, but not necessarily, G<sub>0</sub> cells. Application of the present invention to arrest one or more of the cells cycle molecules indicated above may be used to this end.

[0055] The present invention may also be used to direct patterns of gene expression in pluripotent cells in order to produce specific differentiated cell types for use in transplantation to replace diseased or otherwise non-functional tissue. One example of pluripotent cells are the embryonic stem (ES) cells from non-human pre-implantation embryos. It is well known in the art that mouse ES cells can be reintroduced into the blastocyst whereupon they become incorporated into the developing embryo, develop and differentiate into all bodily cell types and structures. ES cells can also be induced to differentiate *in vitro* into a wide range of cell types following the removal of specific growth factors from the culture medium. It is expected that ES cell lines can be established from all mammals and indeed methods for establishing human ES cell lines have already been established. The differentiation of pluripotent cell types into specific cell types requires that certain pathways of gene expression are turned off and others are turned on. The present invention can be applied to eliminate key proteins within such regulatory pathways in order to direct ES and other embryonic cells to differentiate into specific cell types. The invention may therefore be used to interfere with the expression of developmental genes (such as those mentioned herein) to direct cell differentiation along preferred path-



ways. It is also known that certain cell types complete their differentiation upon exit from the cell division cycle. The invention may therefore also be used to inhibit cell cycle regulatory molecules, such as those listed above. These dsRNAs may be used directly or expressed from regulatable promoters to effect the final stages of cell differentiation.

[0056] The invention also provides an isolated mammalian cell containing an expression construct, the construct coding for an RNA which forms a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template, wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

[0057] When used herein, "treatment/therapy" includes any regime that can benefit a human or non-human animal, and "comprising/having" covers anything consisting only of a specified feature/characteristic, as well as anything with that feature/characteristic, but which also has one or more additional features/characteristics.

[0058] Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*.

## Examples

[0059] The present invention will now be described further in the following examples. Reference is made to the accompanying drawings:

Figure 1: *MmGFP* dsRNA specifically abrogates *MmGFP* expression in *MmGFP* transgenic embryos

(a-c) Representative embryos out of 131 embryos obtained from eleven different matings between F1 females and *MmGFP* transgenic males. *MmGFP* transgenic 4-6 cell stage embryos (a), morula (b), blastocysts (c). A similar pattern of GFP expression was obtained after injection of antisense *MmGFP* RNA. (d-f) Representative embryos out of 147 *MmGFP* transgenic embryos that had been injected with *MmGFP* dsRNA at the one cell stage. 4-6 cell stage embryos (d), morula (e), blastocyst (f). (g-i) Representative embryos out of 18 *MmGFP* transgenic embryos that had been injected with *c-mos* dsRNA at the one cell stage. 6 cell stage embryos (g), morula (h), blastocyst (i). Scale bars represent 20 µm. The shading indicates green fluorescence.

Figure 2: Interference with expression of injected synthetic *MmGFP* mRNA.

(a), Wild type morulae injected with *MmGFP* mRNA alone; (b), together with *ECadherin* dsRNA; and (c), together with *MmGFP* dsRNA, at the one cell stage. Scale bars represent 20µm. The shading indicates green fluorescence.

Figure 3: Injection of *E-cadherin* dsRNA to the zygote reduces E-cadherin expression and perturbs the development of the injected embryos.

(a), Immunofluorescent staining of E-cadherin in embryos injected at the one-cell stage with *MmGFP* dsRNA, and cultured for four days *in vitro* until the blastocyst stage. (b), Immunofluorescent staining of E-cadherin in embryos injected at the one-cell stage with *E-cadherin* dsRNA, and cultured for four days *in vitro*. Note the altered development of these embryos. Scale bars represent 20µm. (c), Western blot analysis of E-cadherin expression in zygotes, uninjected morulae (collected at the one-cell stage and cultured *in vitro* for three days), morulae injected at the one-cell stage with 2 mg ml<sup>-1</sup> of *GFP* dsRNA and cultured *in vitro* for three days, morulae injected at the one-cell stage with 2 mg ml<sup>-1</sup> of *E-cadherin* dsRNA and cultured *in vitro* for three days. In each case, proteins were extracted from 15 embryos. This experiment has been repeated three times with the same result. The reduction of signal following *E-cadherin* dsRNA injection was approximately 6.5 fold. Scale bars represent 20µm. The shading indicates chemiluminescence.

Figure 4: Injection of *c-mos* dsRNA in immature oocyte inhibits *c-mos* expression and causes parthenogenetic activation.

(a-d) Examples of parthenogenetically activated eggs obtained after injection of *c-mos* dsRNA in germinal vesicle stage oocytes. (a), Control oocyte arrested in metaphase II; (b), one-cell embryo (white arrow points out the pronucleus); (c), two-cell embryo; (d), four cell embryo. Scale bars represent 20µm. (e), Western blot analysis of *c-mos* expression in oocytes arrested in metaphase II, oocytes injected at the germinal vesicle stage with 2 mg ml<sup>-1</sup> of *MmGFP* dsRNA and cultured *in vitro* during 12 hours, oocytes injected at the germinal vesicle stage with 2 mg ml<sup>-1</sup> of *c-mos* dsRNA and cultured *in vitro* during 12 hours. In each case, proteins were extracted from 35 oocytes. This experiment has been repeated two times with the same result.

Figure 5: Inhibition of gene expression following injection of double stranded RNA is restricted to the clonal lineage derived from the injected cell.

Immunofluorescent staining of E-cadherin in embryos injected in one cell at the two cell stage with *E-cadherin* dsRNA and synthetic mRNA for MmGFP. The left hand panels show single channel (red) fluorescence to reveal E-Cadherin. Note that the staining is markedly reduced in the progeny of the injected cell. These progeny cells are identified in the corresponding second (green) channels as cells expressing MmGFP.

## Methods

### *Collection and culture of oocytes and embryos*

**[0060]** Immature oocytes arrested at prophase I of meiosis were collected from ovaries of 4-6-week-old F1 (CBAXC57Bl) mice in FHM medium (Speciality media, Inc. Lavalette, N.J.) supplemented with Bovine Serum Albumin (BSA) (4 mg ml<sup>-1</sup>). F1 female mice were superovulated by intraperitoneal injections of pregnant mare's serum gonadotrophin (PMSG, 5 i.u) and human chorionic gonadotrophin (hCG) 48-52 hours apart. Fertilised 1 cell embryos were obtained from mated females 20-24 hours after hCG.

### *RNA synthesis and microinjections*

**[0061]** The templates used for RNA synthesis were linearised plasmids. Full length *MmGFP* cDNA (714bp) was cloned into T7TS plasmid (Zernicka-Goetz, *et al. Development* **124**, 1133-1137 (1997)). A KpnI/HindIII fragment of *c-mos* cDNA (550bp) (Colledge *et al, Nature* **370**, 665-68 (1994)) was cloned into Bluescript pSK. A cDNA corresponding to *exon4-exon8* of *E-cadherin* (580bp) (Larue *et al, Proc Nat Acad Sci USA* **92**, 855-859 (1995)) was cloned into Bluescript pKS. RNAs were synthesised using the T3 or T7 polymerases, using the Megascripts kit (Ambion). DNA templates were removed with DNase treatment. The RNA products were extracted with phenol/chloroform, and ethanol precipitated.

**[0062]** To anneal, equimolar quantities of sense and antisense RNA were mixed in the annealing buffer (10mM Tris pH7.4, EDTA 0.1 mM) to a final concentration of 2 µM each, heated for 10 min at 68°C, and incubated at 37°C for 3-4 hrs. To avoid the presence of contaminating single stranded RNA in the dsRNA samples, the preparations were treated with 2µg/ml of RNase T1 (Calbiochem) and 1 µg/ml RNase A (Sigma) for 30 min at 37°C. The dsRNAs were then treated with 140 µg/ml proteinase K (Sigma), phenol/chloroform extracted and ethanol precipitated. Formation of dsRNA was confirmed by migration on an agarose gel: for each dsRNA, the gel mobility was shifted compared to the ssRNAs. For comparison of antisense and double-stranded RNAs, equal masses of RNA were infected.

**[0063]** RNAs were diluted in water, to a final concentration of 2 to 4 mg ml<sup>-1</sup>. The range of effective concentrations is best illustrated by the *c-mos* experiment (Table 2) due to the sensitivity of this biological phenotype. The mRNAs were microinjected into the cytoplasm of the oocytes or embryos, using a constant flow system (Transjector, Eppendorf) as described (Zernicka-Goetz in *Cell lineage and fate determination* (ed. Moody, S. A.) 521-527 (Academic Press, San Diego, CA, 1999)). Each oocyte or embryo was injected with approximately 10pl of dsRNA. Improved penetrance was achieved by using negative capacitance. After microinjection, oocytes and embryos were cultured in KSOM (Speciality media, Inc. Lavalette, N.J.) medium supplemented with 4 mg ml<sup>-1</sup> of BSA, at 37°C in a 5 % CO<sub>2</sub> atmosphere. MmGFP transgenic embryos were observed by confocal microscopy (Biorad 1024 scanning head on a Nikon Eclipse 800 microscope).

### *Immunoblot and immunostaining analysts*

**[0064]** For immunoblot analysis, samples were subjected to SDS-polyacrylamide gel electrophoresis and proteins were transferred to a hybond nitrocellulose membrane (Amersham). Membranes were preincubated in TBST buffer (20mM Tris-HCl, pH8.2, 150mM NaCl, 0.1 % Tween-20) containing 5 % (w/v) non-fat dried milk overnight, to block non-specific binding of antibodies. They were then incubated with the anti-E cadherin antibody (DECMA-1) or the anti-mos antibody (SantaCruz Biotechnology), during 1 hour, washed in TBST, and incubated with the peroxidase conjugated secondary antibody (SantaCruz Biotechnology) for 1 hour, and washed again in TBST. The antibodies were diluted in TBST containing 5% (w/v) non fat dried milk. The secondary antibody was detected by enhanced chemiluminescence (Amersham). For whole mount immunofluorescence with E-cadherin antibody, embryos were fixed in 2 % paraformaldehyde for 20 min at room temperature, followed by permeabilization with 0.1% Triton X-100 for 10 min. After preincubation in 2 % BSA in PBS for 30 min, embryos were incubated with the anti-E cadherin antibody for 1 hour at 37°C, and with a Texas-Red conjugated goat anti-rat antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa., USA), for 1 hour at 37°C. Embryos were observed using the Biorad 1024 laser scanning confocal microscope.

**Example 1 - dsRNA prevents *gfp* transgene expression**

[0065] To determine whether dsRNA might be used to prevent gene expression in the mouse embryo, we developed an experimental test system using a transgenic strain of mice that expresses MmGFP under the control of the Elongation Factor 1  $\alpha$  (E1F $\alpha$ ) promoter (Zernicka-Goetz, M. in *Cell lineage and fate determination* (ed. Moody, S. A.) 521-527 (Academic Press, San Diego, CA, 1999)). This line offered the advantage that GFP expression can be easily visualised in living embryos and, because its function is non-essential, we could monitor any non-specific deleterious effects of dsRNA on embryonic development. In order to avoid the complication of perdurance of maternal gene products, we used heterozygous embryos in which the transgene was paternally derived. The onset of GFP expression in these embryos is seen by the appearance of green cells following the initiation of zygotic transcription at the two cell stage.

[0066] We were able to demonstrate that the injection of *MmGFP* dsRNA into the single cell zygote prevented the onset of the appearance of green fluorescence at the 2-4 cell stages (Fig. 1). After injection, embryos were cultured *in vitro* for 3-4 days to the blastocyst stage. While uninjected embryos expressed MmGFP in the expected manner (Fig. 1a-c), all embryos the injected with Mn dsRNA showed a dramatically decreased green fluorescence throughout this period (Fig. 1d-f), with a minor proportion (6.8%) showing residual green fluorescence. The embryos showed normal pre- and postimplantation development, demonstrating that the injection of dsRNA is not toxic.

[0067] The interference with gene expression is specific because, when we injected an unrelated dsRNA corresponding to a segment of the *c-mos* transcript into MmGFP transgenic embryos, this did not result in a decrease in green fluorescence (Fig. 1g-i). Similarly, injection of dsRNA corresponding to a segment of E-cadherin transcript into transgenic zygotes (59 embryos observed) did not result in a decrease in green fluorescence, and did not shut down protein synthesis via dsRNA kinase, although the genotype of such embryos was abnormal (data not shown, see below). We also found that transgenic zygotes injected with antisense MnRNA retain the green fluorescence at all pre-implantation stages (37 embryos observed - data not shown).

[0068] We also attempted to determine whether expression of MmGFP from capped full length *MmGFP* mRNA could be eliminated by the co-injection of *MmGFP* dsRNA.

[0069] We found that green fluorescence was greatly diminished or abolished in such injected embryos (Fig. 2d). This was in contrast to embryos injected with sense MmGFP RNA or co-injected with both sense MmGFP mRNA and the "irrelevant" dsRNA for E-cadherin (Fig. 2a-b). Thus dsRNA can interfere both with the expression of a chromosomally located gene, and of synthetic mRNA introduced by microinjection.

**Example 2 - Phenocopying an *E-cadherin* knockout**

[0070] We assessed the specific developmental consequences of injecting E-cadherin dsRNA. E-cadherin is both maternally and zygotically expressed during pre-implantation development. Disruption of the *E-cadherin* gene, using homologous recombination to remove regions of the molecule essential for adhesive function, leads to a severe pre-implantation defect. These embryos can initially undergo compaction, due to the presence of maternally expressed E-cadherin. However, they show a defect in cavitation and never form normal blastocysts (Larue, *et al. Proc Natl Acad Sci U S A* **91**, 8263-8267 (1994); Riethmacher, *et al. Proc Natl Acad Sci U S A* **92**, 855-859 (1995)).

[0071] We observed that following injection of *E-cadherin* dsRNA, the phenotype was identical to that of null mutant embryos. Thus, the embryos initially developed normally to the compaction stage of the morula (data not shown). However, only about 30% were able to cavitate, and formed the so called "cysts" but did not form normal blastocysts (Larue, *et al. Proc Natl Acad Sci U S A* **91**, 8263-8267 (1994)) (Table 1). In contrast, the great majority of uninjected embryos or control embryos injected with *MmGFP* dsRNA cavitated and formed normal blastocysts (Table 1).

Table 1.

Phenotypes obtained following injection of <i>E-cadherin</i> dsRNA into zygotes				
<i>dsRNA injected</i>	No. of experiments	No. of embryos	Known null mutant phenotype	Phenotype resulting from <i>E cadherin</i> dsRNA injection
None	6	240	> 90% formed blastocysts (Obsugi, <i>et al. Dev Biol</i> <b>185</b> , 261-271 (1997))	91.6%±18.3% formed blastocysts

Table 1. (continued)

Phenotypes obtained following injection of <i>E-cadherin</i> dsRNA into zygotes				
<i>dsRNA injected</i>	No. of experiments	No. of embryos	Known null mutant phenotype	Phenotype resulting from <i>E cadherin</i> dsRNA injection
<i>gfp</i> (2 mg ml <sup>-1</sup> )	5	89	N.A.*	74.1%±17% formed blastocysts
<i>Ecadherin</i> (2 mg ml <sup>-1</sup> )	5	130	47.5% formed cysts. Remaining failed to develop to this stage (Larue, <i>et al Proc Natl Acad Sci USA</i> <b>91</b> , 8263-8267 (1994); Ohsugi, <i>et al. Dev Biol</i> <b>185</b> , 261-271 (1997))	26.9%±25.6% formed cysts; Remaining failed to develop to this stage

\*N.A.: Not applicable. Mean± s.d. <sup>a</sup> Significantly different from results with *GFP* dsRNA using the  $\chi^2$  test ( $p < 0.05$ ).

**[0072]** The analysis of E-cadherin expression by immunostaining and immunoblotting shows that the expression of E-cadherin is dramatically decreased after *E-cadherin* dsRNA injection (Fig. 3b, c). In contrast, no decrease in E-cadherin expression was observed in the embryos injected with *MmGFP* dsRNA, for which the level of E-cadherin expression was similar to that of the control uninjected embryos (Fig. 3c). The level of E-cadherin at the morula stage in embryos injected with *E-cadherin* dsRNA is lower than in newly fertilised embryos before injection (Fig. 3c). This residual E-cadherin protein may largely reflect persistence of maternally expressed protein whose synthesis ceases during the 2 cell stage (Sefton, *et al, Development* **115**, 313-318 (1992)). This residual maternal protein is present until the late blastocyst stage in homozygous null embryos (Larue, *et al Proc Natl Acad Sci U S A* **91**, 8263-8267 (1994)).

**[0073]** We conclude that injection of *E-cadherin* dsRNA leads to a striking reduction of E-cadherin protein and consequently a similar phenotype to that of the null mutant embryos.

### Example 3 - dsRNA interference in the oocyte

**[0074]** In order to determine whether dsRNA might be used to interfere with maternally expressed genes, we sought a model gene having a characteristic knockout phenotype. *C-mos* is an essential component of cytotstatic factor, responsible for arresting the maturing oocyte at metaphase in the second meiotic division. In *c-mos*<sup>-/-</sup> mice, between 60 and 75 % of oocytes do not maintain this metaphase II arrest and initiate parthenogenetic development (Colledge, *et al, Nature* **370**, 65-68 (1994); Hashimoto, *et al. Nature* **370**, 68-71 (1994)). *C-mos* mRNA is present in fully grown immature oocytes, and its translation is initiated from maternal templates when meiosis resumes following germinal vesicle breakdown (Verlhac, *et al. Development* **122**, 815-822 (1996)). Thus, injection of *c-mos* dsRNA would allow us to test whether dsRNA could interfere with maternal mRNA expression.

**[0075]** When we injected *c-mos* dsRNA into oocytes, about 63 % did not maintain arrest in metaphase II (Table 2). Of these, 78% initiated parthenogenetic development and progressed to 2 to 4 cell stage embryos (Fig. 4a, b, c). The remainder underwent fragmentation. Both of these events occur at similar frequencies in null mutant oocytes (Colledge, *et al, Nature* **370**, 65-68 (1994)). In contrast, only 1-2% of control oocytes, either uninjected or injected with *MmGFP* dsRNA, underwent spontaneous activation (Table 2). We were still able to observe that 42 % of injected oocytes failed to undergo metaphase II arrest, when we reduced the concentration of injected *c-mos* dsRNA by 20 fold to 0.1 mg/ml (Table 2). This is a significantly higher concentration than that believed to be effective in *C. elegans* and plants, where it is claimed that an effect can be achieved with a few molecules of dsRNA per cell.

Table 2.

Phenotypes observed following injections of <i>c-mos</i> dsRNA in the germinal vesicle stage oocyte				
<i>DsRNA injected</i>	No. of experiments	No. of oocytes	Known null mutant phenotype	Phenotype resulting from <i>dsRNA</i> injections
None	1	158	N.A*	1.3±2% spontaneous activation; 3.8±5.8% fragmentation
<i>Ds gfp</i> (2 mg ml <sup>-1</sup> )	4	73	N.A *	1.4±2.1% spontaneous activation; 2.7±2% fragmentation
<i>Ds mos</i> (2 mg ml <sup>-1</sup> )	4	108	60-75% released from the metaphase II arrest. High degree of cytoplasmic fragmentation (Colledge, <i>et al. Nature</i> <b>370</b> , 65-68 (1994); Hashimoto, <i>et al. Nature</i> <b>370</b> , 68-71 (1994))	49.1 ± 27 % <sup>a</sup> released from the metaphase II block; 13.9±13% fragmentation
<i>Ds mos</i> (0.1 mg ml <sup>-1</sup> )	2	33	as above	36.4±7.6% <sup>b</sup> released from the metaphase II block; 6.1±1.9% fragmentation

\*N.A.: Not applicable. We observed that uninjected oocytes rarely underwent spontaneous activation and at a similar frequency to those injected with *GFP* dsRNA.mean ± s.d.

<sup>a,b</sup> Significantly different from results with *GFP* dsRNA using the  $\chi^2$  test ( $p < 0.05$ )

**[0076]** We confirmed that *c-mos* dsRNA interferes with *c-mos* expression by immunoblot analysis carried out 12 hours after the injection of germinal vesicle stage oocytes before the phenotype consequences of its loss of expression become apparent (Fig. 4e). Thus, injection of *c-mos* dsRNA into the oocyte specifically interferes with *c-mos* activity to mimic the targeted deletion of *c-mos* via homologous recombination. These experiments show that dsRNA is able to block the expression of maternally provided gene products.

#### Example 4 - the effects of RNAi are clonally inherited within the mouse embryo

**[0077]** To assess whether it would be possible to eliminate the expression of specific genes within defined lineages of cells within the early mouse embryo, dsRNA to *E-cadherin* was microinjected into one cell of a two cell stage mouse embryo, together with synthetic mRNA for MmGFP to mark the injected cell. The expression levels of E-cadherin and MmGFP was followed as these embryos developed. The expression of E-cadherin was reduced specifically in cells derived from the one injected with ds *E-cadherin* RNA, the clone being marked by the expression of MmGFP translated from the injected mRNA into the same cell. Thus, in the early mouse embryo, the effect of dsRNA is not transmitted to neighbouring cells. Thus, dsRNAi can be used in the embryo to regulate patterns of gene expression differentially between lineages having with different fates.

#### Discussion

**[0078]** We have demonstrated that dsRNA can be used as a specific inhibitor of gene activity in the mouse oocyte and pre-implantation or early embryo. We show the specificity of the procedure by individually inhibiting the expression of 3 different genes: *c-mos* in the oocyte, and *E-cadherin* or a *gfp* transgene in the early embryo. In the cases of the two endogenous mouse genes, this results in phenotypes comparable to those of null mutants. Our experiments to prevent expression of the *gfp* transgene indicate that RNAi *per se* does not affect the normal course of development.

**[0079]** Two of our experiments support the hypothesis that RNAi acts in the mouse by either inducing degradation

of the targeted RNA, or inhibiting its translation. First we show that injection of *MmGFP* dsRNA inhibits the expression of co-injected sense *MmGFP* mRNA. Secondly, we injected dsRNA against *c-mos* into oocytes before the germinal vesicle breaks down, the stage when *c-mos* mRNA has accumulated but has not yet been translated. *C-mos* is translated when the germinal vesicle breaks down, to arrest oocytes in metaphase II of the second meiotic division. We found that *c-mos* dsRNA prevents its function; oocytes proceed through metaphase II and undergo parthenogenetic activation. In each case, the effects of RNAi persist for sufficient time to phenocopy the loss of gene function. When dsRNA is introduced into early blastocysts, it remains effective until early post-implantation stages. The clonal inheritance of the RNAi effect indicates that it may be targeted towards a pattern of gene activity in a specific lineage. Finally, as RNAi functions in peri-implantation development, it may be expected to result in elimination of expression of target genes in embryonic stem cells established from mouse embryos at this developmental stage, and this may facilitate their directed differentiation into specific cell types.

## Claims

1. An RNA comprising a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene in a mammalian cell or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template, or an expression vector encoding such an RNA, for use as a medicament.
2. The RNA, or expression vector encoding such an RNA, as claimed in claim 1, wherein the target gene is an endogenous gene.
3. The RNA, or expression vector encoding such an RNA, as claimed in claim 1, wherein the target gene is a viral gene.
4. The RNA, or expression vector encoding such an RNA, as claimed in any preceding claim, wherein the dsRNA is not derived from the gene encoding  $\beta$ -glucuronidase.
5. The RNA, or expression vector encoding such an RNA, as claimed in any preceding claim, wherein the RNA comprises a single self-complementary RNA strand.
6. The RNA, or expression vector encoding such an RNA, as claimed in any one of claims 1 to 4, wherein the RNA comprises two separate complementary RNA strands.
7. The RNA, or expression vector encoding such an RNA, as claimed in any preceding claim, wherein the nucleotide sequence is at least 80% identical to the whole of the target gene.
8. The RNA, or expression vector encoding such an RNA, as claimed in any preceding claim, wherein the nucleotide sequence has 90%, 95% or 100% identity with at least a part of the target gene.
9. The use of an RNA, or expression vector encoding such an RNA, as defined in any preceding claim, in the manufacture of a medicament for inhibiting the expression of a target gene in a mammalian cell, wherein the target gene causes or is likely to cause disease and wherein the mammalian cell is a somatic cell or a cell of a non-human pre-implantation embryo.
10. The use as claimed in claim 9, wherein the gene is BCL2.
11. The use as claimed in claim 9 or claim 10, wherein the pre-implantation embryo is a blastocyste.
12. The use as claimed in any one of claims 9 to 11, wherein the cell of the pre-implantation embryo is an embryonic stem cell.
13. A pharmaceutical formulation comprising RNA which comprises a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene in a mammalian cell or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from

an endogenous template, or an expression vector encoding such an RNA, together with a pharmaceutically acceptable carrier, wherein the RNA is not derived from the gene encoding  $\beta$ -glucuronidase and wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

14. A pharmaceutical formulation as claimed in claim 13, modified by the features of any one of claims 3 to 12.

15. A kit for inhibiting expression of a target gene in a mammalian cell, the kit comprising:

RNA which comprises a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene in the mammalian cell or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template or an expression vector encoding such an RNA; and

a vehicle that promotes introduction of the RNA or vector to the mammalian cell,

wherein the RNA is not derived from the gene encoding  $\beta$ -glucuronidase and wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

16. A kit as claimed in claim 15, modified by the features of any one of claims 3 to 12.

17. An isolated mammalian cell containing an expression construct, the construct coding for an RNA which forms a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of a target gene or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template, wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

18. A transgenic non-human mammal containing a cell as claimed in claim 17.

19. An *in vitro* method for inhibiting the expression of a target gene in a mammalian cell, the method comprising:

introducing into the cell an RNA comprising a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of the target gene or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template; and  
verifying inhibition of expression of the target gene,

wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

20. A method as claimed in claim 19, wherein the target gene is an endogenous gene.

21. A method as claimed in claim 19, wherein the target gene is a viral gene.

22. A method as claimed in claim 19, 20 or 21, wherein the RNA is produced outside the cell.

23. A method as claimed in claim 22, wherein the RNA is injected into the cell.

24. A method as claimed in claim 19, 20 or 21, wherein the RNA is produced within the cell.

25. A method as claimed in claim 22, 23 or 24, wherein the RNA is produced recombinantly.

26. A method as claimed in claim 24 or claim 25, wherein the RNA is produced by an expression vector in the cell.

27. A method as claimed in any one of claims 19 to 26, wherein the dsRNA is not derived from the gene encoding  $\beta$ -glucuronidase.



28. A method as claimed in any one of claims 19 to 27, wherein the RNA comprises a single self-complementary RNA strand.

29. A method as claimed in any one of claims 19 to 27, wherein the RNA comprises two separate complementary RNA strands.

30. A method as claimed in any one of claims 19 to 29, wherein the nucleotide sequence is at least 80% identical to the whole of the target gene.

31. A method as claimed in any one of claims 19 to 30, wherein the nucleotide sequence has 90%, 95% or 100% identity with at least a part of the target gene.

32. A method as claimed in any one of claims 19 to 31, wherein the target gene causes or is likely to cause disease.

33. A method as claimed in any one of claims 19 to 32, wherein the pre-implantation embryo is a blastocyte.

34. A method as claimed in any one of claims 19 to 33, wherein the cell of the pre-implantation embryo is an embryonic stem cell.

35. An *in vitro* method for inhibiting the expression of a target gene in a mammalian cell, the method comprising:

introducing into the cell an RNA comprising a double stranded structure having a nucleotide sequence which is at least 80% identical to at least a part of the target gene or is capable of hybridising with a portion of the target gene transcript under the following conditions: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C hybridisation for 12-16 hours, followed by washing, and which is derived from an endogenous template, wherein the dsRNA is not derived from  $\beta$ -glucuronidase wherein the mammalian cell is a somatic cell, a non-human oocyte or a cell of a non-human pre-implantation embryo.

## Patentansprüche

1. RNA, welche eine Doppelstrangstruktur mit einer Nukleotidsequenz aufweist, welche zumindest zu 80 % identisch mit zumindest einem Teil eines Zielgens in einer Säugetierzelle ist oder welche in der Lage ist, mit einem Teil des Zielgentranscripts, unter den folgenden Bedingungen zu hybridisieren: 400 mM NaCl, 40 mM PIPES pH 6,4, 1 mM EDTA, Hybridisierung bei 50°C oder 70°C für 12-16 Stunden, gefolgt von einer Waschung, und welche von einer endogenen Matrize abgeleitet ist, oder ein Expressionsvektor, welcher eine solche RNA codiert, zur Verwendung als Medikament.

2. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach Anspruch 1, wobei das Zielgen ein endogenes Gen ist.

3. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach Anspruch 1, wobei das Zielgen ein Virusgen ist.

4. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach einem der vorhergehenden Ansprüche, wobei die dsRNA nicht von dem Gen abgeleitet ist, welches  $\beta$ -Glucuronidase codiert.

5. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach einem der vorhergehenden Ansprüche, wobei die RNA einen einzelnen selbst-komplementären RNA-Strang aufweist.

6. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach einem der Ansprüche 1 bis 4, wobei die RNA zwei separate komplementäre RNA-Stränge aufweist.

7. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach einem der vorhergehenden Ansprüche, wobei die Nukleotidsequenz zumindest zu 80% identisch mit den gesamten Zielgen ist

8. RNA oder Expressionsvektor, welcher eine solche RNA codiert, nach einem der vorhergehenden Ansprüche, wobei die Nukleotidsequenz 90%, 95% oder 100% Identität mit zumindest einem Teil des Zielgens aufweist.

9. Verwendung einer RNA oder eines Expressionsvektor, welcher eine solche RNA codiert, nach einem der vorhergehenden Ansprüche, bei der Herstellung eines Medikamentes zur Hemmung der Expression eines Zielgens in einer Säugetierzelle, wobei das Zielgen Krankheiten verursacht oder diese sehr wahrscheinlich verursacht, und wobei die Säugetierzelle eine somatische Zelle oder eine Zelle eines nichthumanen Präimplantationsembryos ist

10. Verwendung nach Anspruch 9, wobei das Gen BCL2 ist

11. Verwendung nach Anspruch 9 oder 10, wobei der Präimplantationsembryo ein Blastozyt ist.

12. Verwendung nach einem der Ansprüche 9 bis 11, wobei die Zelle des Präimplantationsembryos eine embryonale Stammzelle ist.

13. Pharmazeutische Formulierung, welche eine RNA umfasst, welche eine Doppelstrangstruktur mit einer Nukleotidsequenz aufweist, welche zumindest zu 80% identisch mit zumindest einem Teil eines Zielgens in einer Säugetierzelle ist oder welche in der Lage ist, mit einem Teil des Zielgentranscripts, unter den folgenden Bedingungen zu hybridisieren: 400 mM NaCl, 40 mM PIPES pH 6,4, 1 mM EDTA, Hybridisierung bei 50°C oder 70°C für 12-16 Stunden, gefolgt von einer Waschung, und welche von einer endogenen Matrize abgeleitet ist, oder einen Expressionsvektor, welcher eine solche RNA codiert, zusammen mit einer pharmazeutisch akzeptablen Trägersubstanz, wobei die RNA nicht von dem Gen abgeleitet ist, welches  $\beta$ -Glucuronidase codiert, und wobei die Säugetierzelle eine somatische Zelle, eine nichthumane Oozyte oder eine Zelle eines nichthumanen Präimplantationsembryos ist

14. Pharmazeutische Formulierung nach Anspruch 13, modifiziert durch die Merkmale nach einem der Ansprüche 3 bis 12.

15. Kit zur Hemmung der Expression eines Zielgens in einer Säugetierzelle, wobei das Kit Folgendes umfasst:

eine RNA, welche eine Doppelstrangstruktur mit einer Nukleotidsequenz aufweist, welche zumindest zu 80% identisch mit zumindest einem Teil eines Zielgens in der Säugetierzelle ist oder welche in der Lage ist, mit einem Teil des Zielgentranscripts, unter den folgenden Bedingungen zu hybridisieren: 400 mM NaCl, 40 mM PIPES pH 6,4, 1 mM EDTA, Hybridisierung bei 50°C oder 70°C für 12-16 Stunden, gefolgt von einer Waschung, und welche von einer endogenen Matrize abgeleitet ist, oder ein Expressionsvektor, welcher eine solche RNA codiert;

und

ein Vehikel, welches die Einführung der RNA oder des Vektors in die Säugetierzelle fördert,

wobei die RNA nicht von dem Gen abgeleitet ist, welches  $\beta$ -Glucuronidase codiert, und wobei die Säugetierzelle eine somatische Zelle, eine nichthumane Oozyte oder eine Zelle eines nichthumanen Präimplantationsembryos ist.

16. Kit nach Anspruch 15, modifiziert durch die Merkmale nach einem der Ansprüche 3 bis 12.

17. Isolierte Säugetierzelle, welche ein Expressionskonstrukt enthält, wobei das Konstrukt eine RNA codiert, welche eine Doppelstrangstruktur mit einer Nukleotidsequenz bildet, welche zumindest zu 80% identisch mit zumindest einem Teil eines Zielgens ist oder welche in der Lage ist, mit einem Teil des Zielgentranscripts, den folgenden Bedingungen zu hybridisieren: 400 mM NaCl, 40 mM PIPES pH 6,4, 1 mM EDTA, Hybridisierung bei 50°C oder 70°C für 12-16 Stunden, gefolgt von einer Waschung, und welche von einer endogenen Matrize abgeleitet ist, wobei die Säugetierzelle eine somatische Zelle, eine nichthumane Oozyte oder eine Zelle eines nichthumanen Präimplantationsembryos ist.

18. Transgenes nichthumanes Säugetier, welches eine Zelle nach Anspruch 17 aufweist.

19. *In vitro*-Verfahren zur Hemmung der Expression eines Zielgens in einer Säugetierzelle, wobei das Verfahren Folgendes aufweist:

das Einführen einer RNA in die Zelle, welche eine Doppelstrangstruktur mit einer Nukleotidsequenz aufweist, welche zumindest zu 80% identisch mit zumindest einem Teil eines Zielgens ist oder welche in der Lage ist, mit einem Teil des Zielgentranscripts, unter den folgenden Bedingungen zu hybridisieren: 400 mM NaCl, 40 mM PIPES pH 6,4, 1 mM EDTA, Hybridisierung bei 50°C oder 70°C für 12-16 Stunden, gefolgt von einer Waschung, und welche von einer endogenen Matrize abgeleitet ist; und

das Nachweisen der Hemmung der Expression der Zielzelle,  
wobei die Säugetierzelle eine somatische Zelle, eine nichthumane Oozyte oder eine Zelle eines nicht-humanen Präimplantationsembryos ist.

- 5 20. Verfahren nach Anspruch 19, wobei das Zielgen ein endogenes Gen ist.
21. Verfahren nach Anspruch 19, wobei das Zielgen ein Virusgen ist.
22. Verfahren nach Anspruch 19, 20 oder 21, wobei die RNA außerhalb der Zelle hergestellt wird.
- 10 23. Verfahren nach Anspruch 22, wobei die RNA in die Zelle injiziert wird.
24. Verfahren nach Anspruch 19, 20 oder 21, wobei die RNA innerhalb der Zelle hergestellt wird.
- 15 25. Verfahren nach Anspruch 22, 23 oder 24, wobei die RNA rekombinant hergestellt wird.
26. Verfahren nach Anspruch 24 oder 25, wobei die RNA durch einen Expressionsvektor in der Zelle hergestellt wird.
27. Verfahren nach einem der Ansprüche 19 bis 26, wobei die dsRNA nicht von dem Gen abgeleitet ist, welches  
20  $\beta$ -Glucuronidase codiert
28. Verfahren nach einem der Ansprüche 19 bis 27, wobei die RNA einen einzelnen selbst-komplementären RNA-Strang aufweist.
- 25 29. Verfahren nach einem der Ansprüche 19 bis 27, wobei die RNA zwei separate komplementäre RNA-Stränge umfasst
30. Verfahren nach einem der Ansprüche 19 bis 29, wobei die Nukleotidsequenz zumindest zu 80% identisch mit dem gesamten Zielgen ist.
- 30 31. Verfahren nach einem der Ansprüche 19 bis 30, wobei die Nukleotidsequenz 90%, 95% oder 100% Identität mit zumindest einem Teil des Zielgens aufweist.
32. Verfahren nach einem der Ansprüche 19 bis 31, wobei das Zielgen Krankheiten verursacht oder sehr wahrscheinlich verursacht.
- 35 33. Verfahren nach einem der Ansprüche 19 bis 32, wobei der Präimplantationsembryo ein Blastozyt ist.
34. Verfahren nach einem der Ansprüche 19 bis 33, wobei die Zelle des Präimplantationsembryos eine embryonale Stammzelle ist.
- 40 35. *In vitro*-Verfahren zur Hemmung der Expression eines Zielgens in einer Säugetierzelle, wobei das Verfahren Folgendes aufweist:  
45 das Einführen einer RNA in die Zelle, welche eine Doppelstrangstruktur mit einer Nukleotidsequenz aufweist, welche zumindest zu 80% identisch mit zumindest einem Teil eines Zielgens ist oder welche in der Lage ist, mit einem Teil des Zielgentranscripts, unter den folgenden Bedingungen zu hybridisieren: 400 mM NaCl, 40 mM PIPES pH 6,4, 1 mM EDTA, Hybridisierung bei 50°C oder 70°C für 12-16 Stunden, gefolgt von einer Waschung, und welche von einer endogenen Matrize abgeleitet ist, wobei die dsRNA nicht von  $\beta$ -Glucuronidase abgeleitet ist, und wobei die Säugetierzelle eine somatische Zelle, eine nichthumane Oozyte oder eine Zelle eines nichthumanen Präimplantationsembryos ist.  
50

## Revendications

- 55 1. ARN comprenant une structure bicaténaire présentant une séquence de nucléotides qui est au moins identique à 80% à au moins une partie d'un gène cible dans une cellule mammalienne ou qui peut réaliser une hybridation avec une partie du transcrit d'un gène cible dans les conditions suivantes : NaCl 400 mM, PIPES 40 mM pH 6,4,

EDTA 1 mM, hybridation à 50°C ou 70°C pendant 12-16 heures, suivie par un lavage, et qui provient d'une matrice endogène, ou un vecteur d'expression codant pour un tel ARN, en vue d'une utilisation en tant que médicament.

2. ARN, ou vecteur d'expression codant pour un tel ARN, selon la revendication 1, dans lequel le gène cible est un gène endogène.
3. ARN, ou vecteur d'expression codant pour un tel ARN, selon la revendication 1, dans lequel le gène cible est un gène viral.
4. ARN, ou vecteur d'expression codant pour un tel ARN, selon l'une quelconque des revendications précédentes, dans lequel l'ARNds ne provient pas du gène codant pour la  $\beta$ -glucuronidase.
5. ARN, ou vecteur d'expression codant pour un tel ARN, selon l'une quelconque des revendications précédentes, dans lequel l'ARN comprend un simple brin d'ARN auto-complémentaire.
6. ARN, ou vecteur d'expression codant pour un tel ARN, selon l'une quelconque des revendications 1 à 4, dans lequel l'ARN comprend deux brins séparés d'ARN complémentaires.
7. ARN, ou vecteur d'expression codant pour un tel ARN, selon l'une quelconque des revendications précédentes, dans lequel la séquence de nucléotides est au moins identique à 80% à l'entièreté du gène cible.
8. ARN, ou vecteur d'expression codant pour un tel ARN, selon l'une quelconque des revendications précédentes, dans lequel la séquence de nucléotides est identique à raison de 90%, 95% ou 100% avec au moins une partie du gène cible.
9. Utilisation d'un ARN, ou d'un vecteur d'expression codant pour un tel ARN, comme défini selon l'une quelconque des revendications précédentes, dans la fabrication d'un médicament pour inhiber l'expression d'un gène cible dans une cellule mammalienne, dans laquelle le gène cible provoque ou est susceptible de provoquer une maladie et dans laquelle la cellule mammalienne est une cellule somatique ou une cellule d'un embryon non humain préimplantatoire.
10. Utilisation selon la revendication 9, dans laquelle le gène est BCL2.
11. Utilisation selon la revendication 9 ou la revendication 10, dans laquelle l'embryon préimplantatoire est un blastocyte.
12. Utilisation selon l'une quelconque des revendications 9 à 11, dans laquelle la cellule de l'embryon préimplantatoire est une cellule souche embryonnaire.
13. Formulation pharmaceutique comprenant un ARN qui comprend une structure bicaténaire présentant une séquence de nucléotides qui est au moins identique à 80% à au moins une partie d'un gène cible dans une cellule mammalienne ou qui peut réaliser une hybridation avec une partie du transcrit d'un gène cible dans les conditions suivantes : NaCl 400 mM, PIPES 40 mM pH 6,4, EDTA 1 mM, hybridation à 50°C ou 70°C pendant 12-16 heures, suivie par un lavage, et qui provient d'une matrice endogène, ou un vecteur d'expression codant pour un tel ARN, ensemble avec un véhicule pharmaceutiquement acceptable, dans laquelle l'ARN ne provient pas du gène codant pour la  $\beta$ -glucuronidase et dans laquelle la cellule mammalienne est une cellule somatique, un ovocyte non humain ou une cellule d'un embryon non humain préimplantatoire.
14. Formulation pharmaceutique selon la revendication 13, modifiée par les caractéristiques de l'une quelconque des revendications 3 à 12.
15. Kit pour inhiber l'expression d'un gène cible dans une cellule mammalienne, le kit comprenant :  
un ARN qui comprend une structure bicaténaire présentant une séquence de nucléotides qui est au moins identique à 80% à au moins une partie d'un gène cible dans la cellule mammalienne ou qui peut réaliser une hybridation avec une partie du transcrit d'un gène cible dans les conditions suivantes : NaCl 400 mM, PIPES 40 mM pH 6,4, EDTA 1 mM, hybridation à 50°C ou 70°C pendant 12-16 heures, suivie par un lavage, et qui provient d'une matrice endogène ou un vecteur d'expression codant pour un tel ARN; et

un véhicule qui promeut l'introduction de l'ARN ou du vecteur dans la cellule mammalienne,

dans lequel l'ARN ne provient pas du gène codant pour la  $\beta$ -glucuronidase et dans lequel la cellule mammalienne est une cellule somatique, un ovocyte non humain ou une cellule d'un embryon non humain préimplantatoire.

16. Kit selon la revendication 15, modifié par les caractéristiques de l'une quelconque des revendications 3 à 12.

17. Cellule mammalienne isolée contenant une construction d'expression, la construction codant pour un ARN qui forme une structure bicaténaire présentant une séquence de nucléotides qui est au moins identique à 80% à au moins une partie d'un gène cible ou qui peut réaliser une hybridation avec une partie du transcrit d'un gène cible dans les conditions suivantes : NaCl 400 mM, PIPES 40 mM pH 6,4, EDTA 1 mM, hybridation à 50°C ou 70°C pendant 12-16 heures, suivie par un lavage, et qui provient d'une matrice endogène, dans laquelle la cellule mammalienne est une cellule somatique, un ovocyte non humain ou une cellule d'un embryon non humain préimplantatoire.

18. Mammifère transgénique non humain contenant une cellule selon la revendication 17.

19. Procédé *in vitro* pour inhiber l'expression d'un gène cible dans une cellule mammalienne, le procédé comprenant :

l'introduction dans la cellule d'un ARN comprenant une structure bicaténaire présentant une séquence de nucléotides qui est au moins identique à 80% à au moins une partie du gène cible ou qui peut réaliser une hybridation avec une partie du transcrit du gène cible dans les conditions suivantes : NaCl 400 mM, PIPES 40 mM pH 6,4, EDTA 1 mM, hybridation à 50°C ou 70°C pendant 12-16 heures, suivie par un lavage, et qui provient d'une matrice endogène; et  
la vérification de l'inhibition de l'expression du gène cible,

dans lequel la cellule mammalienne est une cellule somatique, un ovocyte non humain ou une cellule d'un embryon non humain préimplantatoire.

20. Procédé selon la revendication 19, dans lequel le gène cible est un gène endogène.

21. Procédé selon la revendication 19, dans lequel le gène cible est un gène viral.

22. Procédé selon la revendication 19, 20 ou 21, dans lequel on produit l'ARN à l'extérieur de la cellule.

23. Procédé selon la revendication 22, dans lequel on injecte l'ARN dans la cellule.

24. Procédé selon la revendication 19, 20 ou 21, dans lequel on produit l'ARN à l'intérieur de la cellule.

25. Procédé selon la revendication 22, 23 ou 24, dans lequel on produit l'ARN de manière recombinante.

26. Procédé selon la revendication 24 ou la revendication 25, dans lequel on produit l'ARN par un vecteur d'expression dans la cellule.

27. Procédé selon l'une quelconque des revendications 19 à 26, dans lequel l'ARNds ne provient pas du gène codant pour la  $\beta$ -glucuronidase.

28. Procédé selon l'une quelconque des revendications 19 à 27, dans lequel l'ARN comprend un simple brin d'ARN auto-complémentaire.

29. Procédé selon l'une quelconque des revendications 19 à 27, dans lequel l'ARN comprend deux brins séparés d'ARN complémentaires.

30. Procédé selon l'une quelconque des revendications 19 à 29, dans lequel la séquence de nucléotides est au moins identique à 80% à l'entièreté du gène cible.

31. Procédé selon l'une quelconque des revendications 19 à 30, dans lequel la séquence de nucléotides présente

une identité de 90%, 95% ou 100% avec au moins une partie du gène cible.

32. Procédé selon l'une quelconque des revendications 19 à 31, dans lequel le gène cible provoque ou est susceptible de provoquer une maladie.

33. Procédé selon l'une quelconque des revendications 19 à 32, dans lequel l'embryon préimplantatoire est un blastocyte.

34. Procédé selon l'une quelconque des revendications 19 à 33, dans lequel la cellule de l'embryon préimplantatoire est une cellule souche embryonnaire.

35. Procédé *in vitro* pour inhiber l'expression d'un gène cible dans une cellule mammalienne, le procédé comprenant :

l'introduction dans la cellule d'un ARN comprenant une structure bicaténaire présentant une séquence de nucléotides qui est au moins identique à 80% à au moins une partie du gène cible qui peut réaliser une hybridation avec une partie du transcrit du gène cible dans les conditions suivantes : NaCl 400 mM, PIPES 40 mM pH 6,4, EDTA 1 mM, hybridation à 50°C ou 70°C pendant 12-16 heures, suivie par un lavage, et qui provient d'une matrice endogène, dans lequel l'ARNds ne provient pas de la  $\beta$ -glucuronidase dans lequel la cellule mammalienne est une cellule somatique, un ovocyte non humain ou une cellule d'un embryon non humain préimplantatoire.




FIG. 1






FIG. 2




FIG. 3




FIG. 4

dsRNAi WORKS IN MOUSE EMBRYO  
IN A SPATIALLY DEFINED MANNER




FIG. 5